BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30762113)

  • 1. Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients.
    Crombé A; Alberti N; Villard N; Pilleul F; Buy X; Le Loarer F; Kind M
    Eur Radiol; 2019 Sep; 29(9):4730-4741. PubMed ID: 30762113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.
    Perret R; Chalabreysse L; Watson S; Serre I; Garcia S; Forest F; Yvorel V; Pissaloux D; Thomas de Montpreville V; Masliah-Planchon J; Lantuejoul S; Brevet M; Blay JY; Coindre JM; Tirode F; Le Loarer F
    Am J Surg Pathol; 2019 Apr; 43(4):455-465. PubMed ID: 30451731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events.
    Kunimasa K; Nakamura H; Sakai K; Tamiya M; Kimura M; Inoue T; Nishino K; Kuhara H; Nakatsuka SI; Nishio K; Imamura F; Kumagai T
    Lung Cancer; 2019 Jun; 132():59-64. PubMed ID: 31097095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.
    Sauter JL; Graham RP; Larsen BT; Jenkins SM; Roden AC; Boland JM
    Mod Pathol; 2017 Oct; 30(10):1422-1432. PubMed ID: 28643792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities.
    Yoshida A; Kobayashi E; Kubo T; Kodaira M; Motoi T; Motoi N; Yonemori K; Ohe Y; Watanabe SI; Kawai A; Kohno T; Kishimoto H; Ichikawa H; Hiraoka N
    Mod Pathol; 2017 Jun; 30(6):797-809. PubMed ID: 28256572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors.
    Matsushita M; Kuwamoto S
    Acta Cytol; 2018; 62(5-6):456-462. PubMed ID: 30286456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.
    Le Loarer F; Watson S; Pierron G; de Montpreville VT; Ballet S; Firmin N; Auguste A; Pissaloux D; Boyault S; Paindavoine S; Dechelotte PJ; Besse B; Vignaud JM; Brevet M; Fadel E; Richer W; Treilleux I; Masliah-Planchon J; Devouassoux-Shisheboran M; Zalcman G; Allory Y; Bourdeaut F; Thivolet-Bejui F; Ranchere-Vince D; Girard N; Lantuejoul S; Galateau-Sallé F; Coindre JM; Leary A; Delattre O; Blay JY; Tirode F
    Nat Genet; 2015 Oct; 47(10):1200-5. PubMed ID: 26343384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMARCA4-deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources.
    Kuwamoto S; Matsushita M; Takeda K; Tanaka N; Endo Y; Yamasaki A; Kohashi K; Oda Y; Horie Y
    Hum Pathol; 2017 Dec; 70():92-97. PubMed ID: 28601660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG PET/CT in a Case of Thoracic SMARCA4-Deficient Undifferentiated Tumor.
    Guo J; Liao Z; Chen Q; Dong A; Huang M
    Clin Nucl Med; 2023 Dec; 48(12):1111-1113. PubMed ID: 37882056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [SMARCA4-deficient primary thoracic sarcoma:a clinicopathological analysis of five cases].
    Zheng MJ; Zheng Q; Wang Y; Shen L; Zhu XZ; Li Y
    Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):537-542. PubMed ID: 31288309
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical characteristics and prognosis analysis of 17 cases of SMARCA4-deficient chest tumors].
    Cao XN; Li Z; Wang QY
    Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
    Wang WN; Liu XT; Liang YM
    Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
    [No Abstract]   [Full Text] [Related]  

  • 13. A Subset of Thoracic SMARCA4-Deficient Undifferentiated Tumors Express GATA3.
    Coconubo DM; Wangsiricharoen S; Pettus JR; Linos K; Pinto A; Wang WL; Kerr DA; Cloutier JM
    Int J Surg Pathol; 2024 Jun; 32(4):684-691. PubMed ID: 37461275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.
    Lin DI; Allen JM; Hecht JL; Killian JK; Ngo NT; Edgerly C; Severson EA; Ali SM; Erlich RL; Ramkissoon SH; Vergilio JA; Ross JS; Elvin JA
    Mod Pathol; 2019 Nov; 32(11):1675-1687. PubMed ID: 31190001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thoracic SMARCA4-deficient undifferentiated tumors mimicking inflammatory lesions.
    Ma P; Cheng A; Song F; Sun Y
    Asian J Surg; 2024 May; 47(5):2290-2291. PubMed ID: 38331614
    [No Abstract]   [Full Text] [Related]  

  • 16. Under the Microscope: A Case Report of Thoracic SMARCA4-Deficient Undifferentiated Tumor with Review of the Literature.
    Mundada M; Mannan KA; Vasu D; Ahmed F; K S
    Turk Patoloji Derg; 2024; 40(2):128-133. PubMed ID: 38265099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desmoid-Type Fibromatosis of the Thorax: CT, MRI, and FDG PET Characteristics in a Large Series From a Tertiary Referral Center.
    Xu H; Koo HJ; Lim S; Lee JW; Lee HN; Kim DK; Song JS; Kim MY
    Medicine (Baltimore); 2015 Sep; 94(38):e1547. PubMed ID: 26402812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor.
    Henon C; Blay JY; Massard C; Mir O; Bahleda R; Dumont S; Postel-Vinay S; Adam J; Soria JC; Le Cesne A
    Ann Oncol; 2019 Aug; 30(8):1401-1403. PubMed ID: 31114851
    [No Abstract]   [Full Text] [Related]  

  • 20. SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma.
    Kolin DL; Dong F; Baltay M; Lindeman N; MacConaill L; Nucci MR; Crum CP; Howitt BE
    Mod Pathol; 2018 Sep; 31(9):1442-1456. PubMed ID: 29700418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.